ReviewJournal of mammary gland biology and neoplasia1997
The epidermal growth factor receptor in breast cancer.
Review in Journal of mammary gland biology and neoplasia, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 63 citations in OpenAlex.
- Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.BMC cancer · 2016Article
- Stiff substrates increase YAP-signaling-mediated matrix metalloproteinase-7 expression.Oncogenesis · 2015Article
- mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.International journal of molecular sciences · 2015Article
- Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.Breast cancer research : BCR · 2011Article
- Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility.Nature cell biology · 2009Article
- Article
- Single-dose clinical pharmacokinetic studies of gefitinib.Clinical pharmacokinetics · 2005Article
- Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.Endocrine-related cancer · 2000Review
- The ErbB receptors as targets for breast cancer therapy.Journal of mammary gland biology and neoplasia · 1999Review
- Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile.Journal of clinical pathology · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidermal growth factor receptor (EGFR)3 is a 170 kD transmembrane tyrosine kinase activated by several ligands. It is required for normal mammary development and lactation and is aberrantly expressed in approximately 40% of breast carcinomas, particularly those with a poor prognostic phenotype. Since EGF receptor levels are elevated in a high proportion of many tumor types its potential as a therapy target is being investigated using the EGF receptor to target toxins, as well as drugs that interfere with signaling and anti-receptor antibodies. These approaches are likely to be most effective when used in the adjuvant situation in combination with chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.